T7671

Myosmine is a minor tobacco alkaloid that is structurally related to nicotine.

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.

Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anticancer activity. It inhibits the production of IL-6 and IL-1β, induces apoptosis, and can be used to prevent inflammation and destruction of cartilage or bone. This makes Golimumab valuable for studying rheumatoid arthritis and cancer.

Satralizumab (SA-237) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), acting in neuromyelitis optica spectrum disorder (NMOSD). It is used in studies of neuromyelitis optica.

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.

Envafolimab (ASC 22) is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), with antitumor activity. It blocks the interaction between PD-L1 and PD-1, and is used in studies of solid tumors.

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.

Muromonab (OKT3) is a murine monoclonal antibody targeting CD3 receptors, blocking all cytotoxic T-cell functions. It reverses acute organ transplant rejection and is used in studies of acute graft rejection.

Myosmine-2,4,5,6-D4 is a deuterated compound of Myosmine. Myosmine (T7671) has a CAS number of 532-12-7. Myosmine (T7671) is a minor tobacco alkaloid that is structurally related to nicotine.